Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.


Professor Simon Hollingsworth

VP, Global Medicine Leader, AstraZenecaSimon J Hollingsworth

Simon is Vice President and Global Medicine Leader at AstraZeneca accountable for the global life-cycle development and commercialisation of Lynparza.  He has >20 years’ experience in drug/therapeutics development across industry and academic careers focused in clinical drug development, clinical and translational science, and precision medicine (oncology, inflammation, cardio-/vascular).  His broad clinical development experience from early candidate nomination to Ph.1 – Ph.3, through registration to commercialisation (including small molecules, biologics, gene/cell therapies) is coupled with varied commercial experience (industry, biotech, commercialised own IP).  Simon also maintains an academic profile as Visiting Professor Division Cancer Studies King’s College London, Fellow Royal College Pathologists, and serves on numerous National and International review panels and advisory boards.

Simon can advise on:

  • Clinical drug development
  • Clinical and translational science
  • Precision medicine
  • Industry / Academia partnerships – collaborating and working in Alliances
  • Drug discovery; target validation through to early clinical development
  • Routes to progress drug discovery and translational projects
  • Career development for early career researchers 

DR rachel hemsley

Global Head of Business Development, Xenogesis Rachel Hemsley

Rachel is responsible for setting and delivering the business strategy and the global expansion of XenoGesis. Rachel was previously the Senior Business Manager at UCL Business plc and has 12 years’ experience in business development involving early stage technology development, securing investment funding, licensing early stage healthcare technology and setting up new companies. Her experience spans across stem cell therapies, gene therapies, diagnostics and medical devices. She was also a director of an ocular gene therapy company, Athena Vision Ltd, which was acquired by its investors MeiraGTX who following this acquisition IPO’d on NASDAQ in 2017 for $75m. Prior to this she worked in senior roles at the University of Leicester, including Intellectual Property Manager and Research and Business Development Officer. Rachel completed her PhD in Protein Biochemistry at the University of Wales Aberystwyth, researching the protein phosphorylation cascades and cell signalling. She has since spent 6 years of post-doctoral research experience at the John Innes centre as well as over 12 years’ experience in translating new technologies into products, including 8 years of drug discovery and development experience.

dr Colin T Dourish

Director and Co-Owner of P1vital and P1vital productsColin T Dourish

Colin has a successful track record in CNS drug discovery and drug development in both major pharmaceutical and biotechnology companies. Prior to co-founding P1vital and P1vital Products, he was Senior Vice President Research and CSO of Vernalis Group plc, Research Director and co-founder of Cerebrus Limited, Director of Neuropharmacology at Wyeth Research and Section Head at Merck.Colin has over 450 publications in scientific and medical journals and has edited four books in the areas of Psychopharmacology, Neuroscience, Neurology and Psychiatry. He is an Honorary Fellow of the Department of Psychiatry at the University of Oxford and formerly a William Pitt Fellow of Pembroke College Cambridge, Visiting Professor of Psychopharmacology at the University of Durham and Visiting Professor of Neuroscience and Psychological Medicine at Imperial College of Science, Technology and Medicine. Dr Dourish received his BSc in Psychology and his PhD and DSc in Psychopharmacology from the Queen’s University of Belfast and carried out postdoctoral research at the Department of Psychiatry, University of Saskatchewan in Canada and at the UCL Queen Square Institute of Neurology in London.

Colin can advise on:

  • Drug discovery in CNS disorders, eating disorders and obesity
  • Routes to progress drug discovery and translational projects
  • Clinical development strategy and operational delivery of projects/products
  • Career development for early career researchers

Dr Anthony brown

VP Business Development & Scientific Liaison, Carrick TherapeuticsAnthony Brown

Over 30 years of experience leading small molecule & biological drug discovery programmes. Primary focus in oncology, immune-oncology, inflammation and fibrosis - covering target identification & validation, R&D, clinical studies (Ph1/2/3), manufacturing and companion diagnostics. Direct experience of and leading M&As, in-licensing, financing through IPOs, private investment and industry/academic grants and founded a number of start-up Biotechs. Director level roles in Biotech, Pharma, academic tech transfer and Not-For-Profit organisations. Founder and owner of Drug Discovery Limited, providing consultancy services to several UK/EU Biotechs, defining and implementing research, clinical and commercialisation plans, developing and leading funding and investment strategies.

Anthony can advise on:

  • Drug discovery of small molecules, biologicals and cell-based therapies
  • Routes to progress drug discovery and translational projects
  • Career development for early career researchers

Please contact the Translational Research Office to arrange a meeting.